Skip to main content
SpringerLink
Log in

The discovery and development of rasagiline as a new anti-Parkinson medication

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. In this reference, the value for chronic clorgyline DA basal level should be 0.9 and not 0.09

References

  • Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525(1):36–44

    Article  CAS  Google Scholar 

  • Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1(8009):439–443

    Article  CAS  Google Scholar 

  • Finberg JPM (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133–152

    Article  CAS  Google Scholar 

  • Finberg JPM, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77(1):13–21

    Article  CAS  Google Scholar 

  • Finberg JPM, Youdim MBH (1985) Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol 85(2):541–546

    Article  CAS  Google Scholar 

  • Finberg JPM, Youdim MBH (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacol 43:1110–1118

    Article  CAS  Google Scholar 

  • Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73(1):65–74

    Article  CAS  Google Scholar 

  • Fowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med Res Revs 4(3):323–358

    Article  CAS  Google Scholar 

  • Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49(1–2):1–20

    Article  CAS  Google Scholar 

  • Gillman PK, Feinberg SS, Fochtmann LJ (2019) Revitalizing monoamine oxidase inhibitors: a call for action. CNS Spectr 1–3

  • Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265(5589):80–81

    Article  CAS  Google Scholar 

  • Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17(7):1285–1297

    Article  CAS  Google Scholar 

  • Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73(1):55–64

    Article  CAS  Google Scholar 

  • Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408

    PubMed  CAS  Google Scholar 

  • Lader MH, Sakalis G, Tansella M (1970) Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 18(1):118–123

    Article  CAS  Google Scholar 

  • Laine K, Anttila M, Huupponen R, Maki-IkolaIkola O, Heinonen E (2000) Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23(1):22–27

    Article  CAS  Google Scholar 

  • Lamensdorf I, Youdim MBH, Finberg JPM (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67(4):1532–1539

    Article  CAS  Google Scholar 

  • Panniset M, Chen JJ, Rhyee SH, Conner J, Mathena J (2014) Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacother 34(12):1250–1258

    Article  CAS  Google Scholar 

  • Perez-Lloret S, Rascol O (2011) Safety of rasagiline for the treatment of Parkinson's disease. Exp Opin Drug Saf 10(4):633–643

    Article  CAS  Google Scholar 

  • Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl. J Neurochem 46:1359–1365

    Article  CAS  Google Scholar 

  • Sader-Mazbar O, Loboda Y, Rabey MJ, Finberg JPM (2013) Increased L-dopa-derived dopamine following selective MAO-A or-B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Br J Pharmacol 170(5):999–1013

    Article  CAS  Google Scholar 

  • Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G et al (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62(1):15–30

    Article  CAS  Google Scholar 

  • Thebault JJ, Guillaume M, Levy R (2004) Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacother 24(10):1295–1305

    Article  CAS  Google Scholar 

  • Tipton KF, Youdim MBH (1983) The assay of monoamine oxidase activity. In: Parvez S, Nagatsu T, Nagatsu I, Parvez H (eds) Methods in biogenic amine research. Elsevier, Amsterdam, pp 441–467

    Google Scholar 

  • Yang HY, Neff NH (1974) The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189(3):733–740

    PubMed  CAS  Google Scholar 

  • Youdim MBH, Finberg JPM (1983). Monoamine oxidase inhibitor antidepressants. In: Grahame-Smith DG, Cowen PJ (eds) Part 1: preclinical psychopharmacology. Excerpta Medica, Amsterdam, pp 38–70

  • Youdim MBH, Finberg J (1985) Monoamine oxidase inhibitor antidepressants. In: Grahame-Smith DG (ed) Psychopharmacology 2: Part 1: preclinical psychopharmacology. Elsevier, Amsterdam, pp 35–70

    Chapter  Google Scholar 

  • Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine Oxidase. In: Trendelenburg U, Weiner N (eds) Handbook of experimental pharmacology, vol 90. Springer, Berlin, pp 119–192

    Google Scholar 

  • Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500–506

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rappaport Faculty of Medicine, Technion, Haifa, Israel

    John P. M. Finberg

Authors
  1. John P. M. Finberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. M. Finberg.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Finberg, J.P.M. The discovery and development of rasagiline as a new anti-Parkinson medication. J Neural Transm 127, 125–130 (2020). https://doi.org/10.1007/s00702-020-02142-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-020-02142-w

Search

Navigation